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Objective: Today, the role of inﬂammation in the pathophysiology of benign prostatic hyperplasia (BPH)
has become quite evident. Numerous markers have been found which suggests a role of non-bacterial
inﬂammation in the prostate. Despite the recommendation of anti-inﬂammatory drugs for BPH,
research on the effectiveness of such drugs is scant. Hence, the present study examined the effectiveness
of celecoxib in treating patients with BPH.
Materials and Methods: This single-blind randomized control trial was conducted on 160 patients referred
to a urology clinic from 2006 to 2007. Patients were aged 50 years, had obstructive and irritative
symptoms of BPH, and had American Urological Association (AUA) scores ranging 7e25. They were
randomly assigned to control (treated with 2 mg terazosin) and celecoxib (2 mg terazosin with 200 mg
celecoxib) groups and underwent 12 weeks of treatment.
Results: The baseline measures for the severity of symptoms, postvoiding residual urine (PVR), prostate
volume, and prostate-speciﬁc antigen (PSA) level did not signiﬁcantly differ between the two groups. The
severity of symptoms and PVR signiﬁcantly decreased after treatment in both groups. However, the
prostate volume and PSA level signiﬁcantly dropped as well in the celecoxib group. The overall severity
of symptoms, irritative symptoms, and prostate volume decreased more in the celecoxib group than in
the control group.
Conclusion: The present study showed that combination therapy with celecoxib and terazosin can
signiﬁcantly decrease irritative symptoms of BPH and prostate volume as well. Therefore, it seems that
adding anti-inﬂammatory drugs to routine treatment for BPH could be more effective than routine
therapy.
Copyright  2011, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Benign prostatic hyperplasia (BPH) is a pathological condition of
the prostate that mainly involves the central zone of the prostate
gland.1 From a histological view, this condition is observed in 8% of
autopsies in men in the third decade of their lives. The prevalence
of this condition increases as men age and reaches 50%, 70%, and
90% in the ﬁfth, seventh, and eighth decades of life, respectively.2
However, a study conducted in the US showed that moderate to
severe urinary symptoms of BPH begin to appear in the third
decade in patients, and its clinical prevalence increases to 45% and
62% in the ﬁfth and seventh decades of life, respectively.3 Despite
not being a life-threatening problem, BPH can affect the quality ofAsr Hospital, Vali Asr Square,
ciation. Published by Elsevier Taiwlife in various ways. In fact, patients with lower urinary tract
symptoms (LUTSs) suffer from various problems in terms of sleep,
daily mobility, household chores, recreational activities, and sexual
relationships.4,5 Nevertheless, only a small percentage of these
patients receive proper diagnosis and treatment.5
There are different treatment options for BPH patients. In cases
of mild to moderate severity which do not result in inconvenience,
watchful waiting treatment is preferred. For patients with more
severe symptoms, surgical or medical treatment may be used
according to the patient’s performance and preferences. Today, the
use of al-adrenergic-receptor antagonists and 5a-reductase inhib-
itors has reduced the tendency for surgery and decreased side
effects, such as retrograde ejaculation, impotence, urinary incon-
tinence, hemorrhage, stricture of the urethra, constriction of the
bladder neck, perforation of the prostatic capsule, and urinary tract
infections.6e8 al-Adrenergic receptor antagonists release the
smooth muscle tone of the prostate gland and the urethra and are
therefore chosen as an effective medication for BPH because ofan LLC. Open access under CC BY-NC-ND license.
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However, these drugs do not result in a change in the prostate
size.9,10 5a-Reductase inhibitors are effective through another
mechanism which causes shrinkage of the prostate via inhibiting
the enzyme converting testosterone to dihydrotestosterone.11 A
combination of these two drugs was examined in several clinical
trials proving their relative superior effectiveness over any mono-
therapy.12e15 However, dizziness, asthenia, nasal congestion,
orthostatic hypotension, impotence, and ejaculation disorders are
common side effects associated with these drugs15 which may be
problematic if patients also have senile conditions, such as cardio-
vascular disease, hypertension, diabetes, metabolic syndrome, and
sexual disorders.2
The role of inﬂammation in the pathophysiology of BPH has
been highlighted in recent years, and various markers were found
to verify the non-bacterial nature of inﬂammation in the prostate.16
In fact, some studies recognized chronic inﬂammation of the
prostate as underlying prostatic hyperplasia and certain urinary
symptoms.17 In another study, the effects of inﬂammatory severity
in pathologic samples obtained through transrectal ultrasonog-
raphy (TRUS)-guided needle biopsy on the symptoms and quality of
life were investigated. They found that a drop in the severity of
symptoms and an increase in the quality of life occurred faster and
were sustained longer in patients with a lesser extent of inﬂam-
mation compared to those with more severe inﬂammation.18 Thus,
medical treatment of prostatic inﬂammation as part of BPH treat-
ment is commonly recommended.18 Despite the recommendation
of anti-inﬂammatory drugs for BPH, research on the effectiveness
of such drugs is scant. Since prostaglandins are key factors in the
development of inﬂammation, cellular invasion, apoptosis, angio-
genesis, and balancing immunological reactions, it seems that
cyclooxygenase (COX)-2 inhibitors may effectively contribute to
decreased inﬂammation of prostatic tissues in BPH and signiﬁ-
cantly reduce symptoms and the prostatic volume. This postulation
is based on the COX-2 enzyme playing an important role in the
synthesis of prostaglandins. Celecoxib is a selective inhibitor of this
enzymewhich was shown to reduce nocturia in BPH patients.19 The
present study therefore examined the effect of celecoxib as
a supplementary medication for BPH on urinary symptoms, post-
voiding residual urine (PVR), prostatic volume, and the PSA level.
2. Materials and methods
2.1. Patient selection
This single-blind randomized control trial was conducted on
patients seeking treatment at the Urology Clinic of Vali Asr
Hospital, Arak, Iran in the period of January 2006 to April 2007.
Patients aged 50 years with irritative and obstructive symptoms
of BPHwere selected. They also had tomeet the following inclusion
criteria: the presence of obstructive-irritative symptoms caused by
BPH; a score of 7e25 on the American Urological Association (AUA)
symptom scale (equal to moderate symptoms); prostatic hyper-
plasia without induration, nodules, or asymmetry on a digital rectal
examination (DRE); unlikely to be afﬂicted with other causes of
LUTSs, such as urinary tract infection, neurogenic bladder, or
urethral constriction based on history taking, clinical examination,
sonography, and laboratory tests; no presence of indications for
prostate surgery, including severe life-threatening symptoms,
persistent urinary retention (failure to discharge without a catheter
with more than one attempt), recurrent urinary tract infection due
to BPH, severe recurrent hematuria, renal failure (high levels of
blood urea nitrogen (BUN) and creatine (Cr)) due to BPH, and
bladder stones caused by BPH; no presence of abnormal PSA, large
bladder diverticula, or gastrointestinal problems, such as pepticulcer; and a lack of history of sensitivity to the treatment drugs
(terazosin and celecoxib).
Satisfaction of the inclusion criteria was conﬁrmed by a urologist
and veriﬁed through digital rectal examination, urine analysis (UA)
and culture (UC), AUA symptom score, and laboratory tests (PSA,
BUN, and Cr). Patients were briefed about the goals of the study and
the likely side effects of the treatment drugs. Informed consent was
obtained from all patients as well. The present study was conducted
in compliance with ethical statements 1 and 2 of the Helsinki
Declaration and all 26 ethical statements established by the Iranian
Ministry of Health. In addition, ethical approval was also received
from the ethics committee of Arak University of Medical Sciences.
Two hundred patients meeting the entry requirements were
randomly assigned to the control and celecoxib groups. However, 40
patients dropped out, and 160 patients (80 in each group) remained
to the end of the treatment for data analysis. Among those 40
patients, 12 patients in the control group and 10 patients in the
celecoxib group failed to follow-up their treatment. In addition,
eight and 10 patients in the control and celecoxib groups, respec-
tively, refused to reevaluate their PSA and sonography.
2.2. Intervention
The control group received terazosin alone (2 mg as a single
dose at night), and the celecoxib group received combination
therapy of terazosin (2 mg as a single dose at night) and celecoxib
(200 mg every 12 hours) for 12 weeks. Terazosin, in the form of a 2-
mg tablet, and celecoxib, in the form of a 200-mg capsule, were
supplied by the Hakim Pharmaceutical Co., Tehran, Iran and the
Darou Pakhsh Pharmaceutical Co. Tehran, Iran, respectively. In
order to prevent hemodynamic effects of terazosin, it was titrated
for both groups in a 1-mg (half tablet) dosage before sleep in the
ﬁrst 2 days and 2mg (full tablet) for the remaining treatment. In the
celecoxib group, however, celecoxib was prescribed twice a day to
be taken along with daily meals.
2.3. Measures
In addition to the foregoing inclusion criteria, the ages of
participants were recorded. A sonography specialist conducted
bladder and prostate sonography to measure the PVR and prostrate
volume. Transrectal sonography used an SIUI CTS 200 Ultrasound
System (Shantou Institute of Ultrasonic Instruments Co., Guang-
dong, China). The prostrate volume was calculated by two circular
or ellipsoidal perpendicular planes according to the prostate shape.
Symptom severity of BPH was measured using the AUA symptom
score by an assistant who was blinded to the individual patient’s
group. The AUA questionnaire measures seven obstructive and
irritative symptoms of BPH, including incomplete emptying,
urination frequency, intermittency, urgency, a weak stream,
straining, and nocturia in the past month. A measure of each
symptom is taken on a 6-point scale, ranging from 0 to 5. The
overall severity is calculated by the addition of individual measures,
ranging from 0 to 35, inwhich a higher score indicates more severe
symptoms. The severity of irritative symptoms was calculated by
adding up individual scores from urination frequency, urgency, and
nocturia. Adding individual scores of the rest of the measures
produced an obstructive symptoms severity score.10 Patients were
visited monthly to evaluate clinical progression, drug compliance,
and side effects during the study period. Sonography reevaluation
was conducted at the end of treatment in order to assess the PVR
and prostate volume. The PSA value and AUA questionnaire were
also re-assessed. Side effects, including hemodynamic conditions
(orthostatic hypotension, fatigue, dizziness and palpitation) and
gastric problems were also recorded.
Table 1
Comparison of the mean (standard deviation) of symptoms severity, postvoiding residual urine, prostate volume and prostate-speciﬁc antigen (PSA) within and between
groups.
Control group (N ¼ 80) Celecoxib group (N ¼ 80) Between-group comparison (pb)
Pre Post pa Pre Post pa Pre Post
AUA symptoms score 17.0  5.7 10.3  4.2 <0.001 16.9  6.1 7.7  4.1 <0.001 0.937 <0.001
Obstructive symptoms severity 9.4  4.2 4.8  2.9 <0.001 9.2  4.4 4.0  2.9 <0.001 0.785 0.067
Irritative symptoms severity 7.6  2.4 5.4  2.1 <0.001 7.7  3.2 3.4  2.3 <0.001 0.800 <0.001
Postvoiding residual urine (mL) 38.5  29.9 22.7  19.5 <0.001 35.6  30.4 20.1  18.6 <0.001 0.547 0.389
Prostate volume (mL) 43.4  18.9 43.0  17.2 0.454 44.0  19.3 38.3  16.8 <0.001 0.840 0.081
PSA (ng/mL) 3.54  3.58 3.17  1.66 0.238 3.36  2.39 2.77  1.74 0.013 0.709 0.143
Note. Statistically signiﬁcant p values between groups are indicated in bold font.
a paired t test
b independent sample t test.
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SPSS 16.0 for Windows (SPSS, Chicago, IL, USA) was used to
perform the required statistical analyses. Datawere described using
the mean and standard deviation. An independent t test was used
to measure variations in age, overall severity of symptoms, severity
of obstructive and irritative symptoms, the PVR, prostate volume,
and PSA level before and after the intervention in the two groups.
To compare changes in these variables after the intervention in
each group, a paired t test was used. A p value of <0.05 was
considered signiﬁcant.
3. Results
The range and mean age  standard deviation of patients were
50e85 and 66  9 years, respectively. The two groups did not
signiﬁcantly differ in the age variable (p ¼ 0.852). Table 1 presents
the baseline measures for the severity of symptoms, PVR, prostate
volume, and PSA levels for these two groups. There was no signif-
icant difference between the two groups. The 12-week treatment in
the celecoxib group signiﬁcantly decreased all measures compared
to the baseline. However, in the control group, the prostate volume
and PSA level did not signiﬁcantly decrease (Table 1). In addition,
the amounts of the decrease in the overall severity of symptoms
and irritative symptoms scores in the celecoxib group were greater
than those of the control group (Table 2).
The hemodynamic side effects associated with terazosin
(orthostatic hypotension, fatigue, dizziness, and palpitations) were
detected in 12 participants from both groups (15%). Gastric prob-
lems were reported by eight (10%) and 12 patients (15%) in the
control and celecoxib groups, respectively. However, the side
effects were not severe enough to interrupt the treatment.
4. Discussion
The ﬁndings in the present study show that 3-month supple-
mentary treatment with celecoxib and terazosin in BPH patientsTable 2
The mean (standard deviation) of decreases in symptoms severity, postvoiding






AUA symptoms score (e6.7)  5.7 (e9.2)  6.9 0.014
Obstructive symptoms severity (e4.5)  3.9 (e5.2)  5.1 0.369
Irritative symptoms severity (e2.2)  2.7 (e4.3)  3.6 <0.001
Postvoiding residual urine (mL) (e15.8)  21.6 (e15.6)  21.7 0.393
Prostate volume (mL) (e0.4)  4.8 (e5.7)  7.0 <0.001
PSA (ng/mL) (e0.38)  2.9 (e0.59)  2.1 0.585
Note. Statistically signiﬁcant p values between groups are indicated in bold font.
a independent sample t test.signiﬁcantly reduced the overall severity of urinary symptoms,
individual obstructive and irritative symptoms, PVR, prostate
volume, and PSA level. However, compared to terazosin-alone
treatment, greater decreases were achieved in the overall severity
of symptoms, severity of irritative symptoms, and prostate volume.
The role of chronic inﬂammation was considered in many
studies. Nickel et al20 in 2008 found that 77.6% of patients with
LUTSs suffered from chronic inﬂammation, and the degree of
chronic inﬂammation corresponded to the severity of symptoms.
Furthermore, advanced prostate hyperplasia and acute urinary
retention caused by chronic and symptom-free inﬂammation of the
prostate were also reported.21e23 In addition, Chuang et al24 also
showed higher serum C-reactive protein (CRP) levels, a widely used
marker of inﬂammation and infection, in BPH patients compared to
asymptomatic controls. So, anti-inﬂammatory treatment for BPH is
reccomended.25 However, little research has been conducted to
verify the effect of anti-inﬂammatory agents on BPH. Falahatkar
et al19 showed that celecoxib treatment can decrease or eliminate
nocturia in more than 80% of participants. Di Silverio et al26 also
showed that rofecoxib (another COX-2 inhibitor) was able to
improve the clinical signs of BPH patients before the emergence of
clinical effects of ﬁnastride. In addition, studies using diclofenac
and indomethacin also showed a decrease in nocturia.27,28 The
results of our study also showed a better response with celecoxib/
terazosin combination treatment than terazosin alone in
decreasing symptoms, particularly irritative ones, and leading to
a decrease in prostate volume as well. As it is known that chronic
inﬂammation of the prostate is related to the higher volume of this
gland20 and terazosin-alone treatment did not result in a reduction
in the prostate volume,29 we may attribute the reduction in the
prostate volume to a decrease in chronic inﬂammation of the gland
by celecoxib.
Various studies showed the expression of COX-2 in prostatic
cells of both BPH and prostatic cancer patients.30e32 Expression of
this isoenzyme in luminal epithelial cells within ducts adjacent to
foci of chronic inﬂammation, which was shown byWang et al,33 led
to a higher proliferation rate and upregulated the antiapoptotic
gene, Bcl-2. Enhanced expression of this gene can deregulate
normal apoptotic cell death mechanisms resulting in imbalanced
growth of prostatic tissue.34e36 So this could be one of the mech-
anisms by which COX-2 inhibitors reduced the prostate volume in
our study. In addition, prostaglandins also play a special role in
urine production.37 Therefore, other effective mechanisms of this
drug in treating LUTSs may be a reduction in urine production by
the kidneys, reduction of inﬂammation of prostatic tissue, and an
indirect effect of these factors on patients’ sleep quality through
a reduction in nocturnal symptoms.19 Furthermore, celecoxib cau-
ses atrophy and reduction of Leydig cells, which in turn reduces the
prostate volume by decreased production of testosterone.38
Since celecoxib only inhibits COX-2, without any effect on COX-1
(which when inhibited causes several side effects, such as gastric
D. Goodarzi et al. / Urological Science 22 (2011) 147e150150ulcers and hemorrhage, renal dysfunction, and inhibition of platelet
aggregation), it causes few gastric, renal, or hemorrhagic prob-
lems.39 Our study also showed few side effects of this drug, which
were too weak to discontinue treatment. Di Silverio et al28 likewise
reported few and weak side effects. Our preliminary study gener-
ally showed that COX-2 inhibitors are well tolerated by patients
and are able to reduce symptoms and prostate volume associated
with BPH.
The problem of distinguishing between chronic prostatitis/
chronic pelvic pain syndrome (CP/CPPS) and LUTSs of BPH is an
important point in the interpretation of our results. However,
according to the greater age of our patients, normal UA and UC
exams, and conﬁrmation of BPH by a urologic examination, it seems
that almost all of our patients suffered from BPH not CPPS. Another
point is that we had no run-in period for excluding noncompliant
subjects, placebo responders, or subjects who could not tolerate or
did not respond to the active drugs, but taking into account the
clear evidence indicating a prostatic inﬂammatory process in BPH
patients and heeding the recommendation for the use of anti-
inﬂammatory drugs, it seems that celecoxib may be effective for
this purpose. Therefore, further research with a larger sample size,
using a run-in period, using other COX-2 inhibitors, using a placebo
group, and if possible, measuring the effect of COX-2 inhibitor
treatment on changes in inﬂammatory biomarkers is needed in
order to examine the precise effect of this group of drugs on BPH
patients and their mechanisms, identify the appropriate dosage
and treatment duration.5. Conclusion
The present study showed that celecoxib/terazosin combination
therapy in BPH patients can reduce the severity of symptoms in
general and irritative ones in particular more than single therapy
with terazosin, and it can also decrease the prostate volume.
Therefore, since prostatic inﬂammation in BPH is conﬁrmed, it
seems that prescribing anti-inﬂammatory drugs for these patients
may prove effective. Therefore, further research with a larger
sample size and use of various COX-2 inhibitors alongside a placebo
group is highly encouraged in order to conductmore-precise studies
on the effectiveness of these anti-inﬂammatory drugs in BPH.References
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